Sarah Hetrick1, Magenta Simmons, Sally Merry. 1. ORYGEN Research Centre & Headspace, National Youth Mental Health Foundation, The Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia. shetrick@unimelb.edu.au
Abstract
OBJECTIVE: In the context of controversy and uncertainty about the role of selective serotonin reuptake inhibitors (SSRIs) for the treatment of depressive disorders in children and adolescents, we consider the evidence of the benefits and risks of this class of medication and the possible role of shared decision-making as a practical way to guide clinicians, young people and their families through treatment decisions. CONCLUSION: We suggest that there is an imperative for clinicians to engage young people in a process of shared decision-making, given the uncertainties about SSRI medication in this age group. Shared decision-making provides a way for clinicians to engage young people and ensure they receive the treatment required for this disorder, the potential outcomes of which are severe.
OBJECTIVE: In the context of controversy and uncertainty about the role of selective serotonin reuptake inhibitors (SSRIs) for the treatment of depressive disorders in children and adolescents, we consider the evidence of the benefits and risks of this class of medication and the possible role of shared decision-making as a practical way to guide clinicians, young people and their families through treatment decisions. CONCLUSION: We suggest that there is an imperative for clinicians to engage young people in a process of shared decision-making, given the uncertainties about SSRI medication in this age group. Shared decision-making provides a way for clinicians to engage young people and ensure they receive the treatment required for this disorder, the potential outcomes of which are severe.
Authors: Magenta B Simmons; Aurora Elmes; Joanne E McKenzie; Lyndal Trevena; Sarah E Hetrick Journal: Health Expect Date: 2016-10-17 Impact factor: 3.377